Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Fady I Malik

Showing results (71-80 of 120) with videos related to

Pageof 12
Sort By:
European Heart Journal|March 24, 2022
Influence of atrial fibrillation on efficacy and safety of omecamtiv mecarbil in heart failure: the GALACTIC-HF trialScott D Solomon, Brian L Claggett, Zi Michael Miao, et al.
Circulation. Heart Failure|December 5, 2025
Efficacy and Safety of Aficamten in Children and Adolescents With Obstructive Hypertrophic Cardiomyopathy: Study Design and Rationale of CEDAR-HCMJuan Pablo Kaski, Paul F Kantor, Stephanie J Nakano, et al.
JAMA Cardiology|October 13, 2021
Assessment of Omecamtiv Mecarbil for the Treatment of Patients With Severe Heart Failure: A Post Hoc Analysis of Data From the GALACTIC-HF Randomized Clinical TrialG Michael Felker, Scott D Solomon, Brian Claggett, et al.
ACS Medicinal Chemistry Letters|April 20, 2018
Discovery of <i>Tirasemtiv</i>, the First Direct Fast Skeletal Muscle Troponin ActivatorScott E Collibee, Gustave Bergnes, Alexander Muci, et al.
European Heart Journal|June 8, 2022
Effects of omecamtiv mecarbil in heart failure with reduced ejection fraction according to blood pressure: the GALACTIC-HF trialMarco Metra, Matteo Pagnesi, Brian L Claggett, et al.
Lancet (London, England)|December 5, 2016
Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure (COSMIC-HF): a phase 2, pharmacokinetic, randomised, placebo-controlled trialJohn R Teerlink, G Michael Felker, John J V McMurray, et al.
Journal of Cardiac Failure|January 12, 2024
Cardiac Troponin and Treatment Effects of Omecamtiv Mecarbil: Results From the GALACTIC-HF StudyG Michael Felker, Scott D Solomon, Marco Metra, et al.
Journal of the American College of Cardiology|September 1, 2024
Effect of Aficamten on Health Status Outcomes in Obstructive Hypertrophic Cardiomyopathy: Results From SEQUOIA-HCMCharles F Sherrod, Sara Saberi, Michael E Nassif, et al.
Journal of Medicinal Chemistry|October 12, 2021
Discovery of Reldesemtiv, a Fast Skeletal Muscle Troponin Activator for the Treatment of Impaired Muscle FunctionScott E Collibee, Gustave Bergnes, Chihyuan Chuang, et al.
Journal of the American College of Cardiology|September 1, 2024
Effect of Aficamten on Cardiac Structure and Function in Obstructive Hypertrophic Cardiomyopathy: SEQUOIA-HCM CMR SubstudyAhmad Masri, Rhanderson N Cardoso, Theodore P Abraham, et al.
Pageof 12

Showing results (71-80 of 120) with videos related to

Sort By:
Pageof 12
European Heart Journal|March 24, 2022
Influence of atrial fibrillation on efficacy and safety of omecamtiv mecarbil in heart failure: the GALACTIC-HF trialScott D Solomon, Brian L Claggett, Zi Michael Miao, et al.
Circulation. Heart Failure|December 5, 2025
Efficacy and Safety of Aficamten in Children and Adolescents With Obstructive Hypertrophic Cardiomyopathy: Study Design and Rationale of CEDAR-HCMJuan Pablo Kaski, Paul F Kantor, Stephanie J Nakano, et al.
JAMA Cardiology|October 13, 2021
Assessment of Omecamtiv Mecarbil for the Treatment of Patients With Severe Heart Failure: A Post Hoc Analysis of Data From the GALACTIC-HF Randomized Clinical TrialG Michael Felker, Scott D Solomon, Brian Claggett, et al.
ACS Medicinal Chemistry Letters|April 20, 2018
Discovery of <i>Tirasemtiv</i>, the First Direct Fast Skeletal Muscle Troponin ActivatorScott E Collibee, Gustave Bergnes, Alexander Muci, et al.
European Heart Journal|June 8, 2022
Effects of omecamtiv mecarbil in heart failure with reduced ejection fraction according to blood pressure: the GALACTIC-HF trialMarco Metra, Matteo Pagnesi, Brian L Claggett, et al.
Lancet (London, England)|December 5, 2016
Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure (COSMIC-HF): a phase 2, pharmacokinetic, randomised, placebo-controlled trialJohn R Teerlink, G Michael Felker, John J V McMurray, et al.
Journal of Cardiac Failure|January 12, 2024
Cardiac Troponin and Treatment Effects of Omecamtiv Mecarbil: Results From the GALACTIC-HF StudyG Michael Felker, Scott D Solomon, Marco Metra, et al.
Journal of the American College of Cardiology|September 1, 2024
Effect of Aficamten on Health Status Outcomes in Obstructive Hypertrophic Cardiomyopathy: Results From SEQUOIA-HCMCharles F Sherrod, Sara Saberi, Michael E Nassif, et al.
Journal of Medicinal Chemistry|October 12, 2021
Discovery of Reldesemtiv, a Fast Skeletal Muscle Troponin Activator for the Treatment of Impaired Muscle FunctionScott E Collibee, Gustave Bergnes, Chihyuan Chuang, et al.
Journal of the American College of Cardiology|September 1, 2024
Effect of Aficamten on Cardiac Structure and Function in Obstructive Hypertrophic Cardiomyopathy: SEQUOIA-HCM CMR SubstudyAhmad Masri, Rhanderson N Cardoso, Theodore P Abraham, et al.
Pageof 12